Urology News and Research

Latest Urology News and Research

Patient-friendly examination method reduces need for prostate cancer biopsies

Each year prostate tissue samples are taken from over a million men around the world - in most cases using 12 large biopsy needles - to check whether they have prostate cancer.

8 Apr 2014

Study shows spinal stimulation therapy may have potential to change prognosis of people with paralysis

Four people with paraplegia are able to voluntarily move previously paralyzed muscles as a result of a novel therapy that involves electrical stimulation of the spinal cord, according to a study funded in part by the National Institutes of Health and the Christopher & Dana Reeve Foundation.

8 Apr 2014

Bladder outlet obstruction shows distinct urodynamic patterns

Chinese researchers have identified a number of distinct urodynamic patterns among older men with non-neurogenic lower urinary tract symptoms and bladder outlet obstruction.

7 Apr 2014

ICIQ bladder diary ‘psychometrically valid’

UK researchers in collaboration with patients and clinicians have developed a new diary to be used to record lower urinary tract symptoms.

7 Apr 2014

Astellas, Medivation submit European Marketing Authorization Application for XTANDI capsules

Astellas Pharma Inc. and Medivation Inc. today announced the submission of a variation to amend the European Marketing Authorization Application for XTANDI® (enzalutamide) capsules for the treatment of adult men with metastatic castration-resistant prostate cancer (mCRPC) who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy and in whom chemotherapy is not yet clinically indicated.

4 Apr 2014

Ketamine offers novel treatment for patients with severe depression

New data show ketamine (a drug widely used for anaesthesia and pain relief) has a rapid antidepressant effect in some patients with severe depression. The first UK study of ketamine intravenous infusions in people with treatment-resistant depression was conducted by the Oxford Health NHS Foundation Trust and the University of Oxford.

3 Apr 2014

Actavis opens new regional headquarters in Singapore

Actavis plc (NYSE: ACT), a leading global specialty pharmaceutical company, today announced the official opening of its new regional office in Singapore that will serve as the headquarters for the Company's Asia Pacific and Africa (APACA) region.

3 Apr 2014

Actavis announces acquisition of Silom Medical for $100 million

Actavis plc, a leading global specialty pharmaceutical company today announced that it has acquired Silom Medical Company, a privately held generic pharmaceutical company focused on developing and marketing therapies in Thailand, for approximately $100 million in cash.

1 Apr 2014

NCCN ORP awarded grant to study effectiveness of enzalutamide in solid tumors

The National Comprehensive Cancer Network Oncology Research Program has been awarded a $2.2-million grant from Astellas Pharma, Inc. and Medivation, Inc. to develop a program to scientifically evaluate and define the clinical effectiveness of enzalutamide in solid tumors, including bladder, breast, endometrial, hepatocellular, ovarian, and prostate cancers.

1 Apr 2014

TUFS tool useful for assessing storage symptoms in OAB

The total urgency and frequency score is a useful tool for assessing changes in major storage symptoms in patients with overactive bladder, researchers believe.

31 Mar 2014

Antimuscarinics plus α-blockers ‘recommended for male LUTS’

Antimuscarinics “could and should” be used in the pharmacological treatment of men with lower urinary tract symptoms caused by benign prostatic hyperplasia or bladder outlet obstruction, say the authors of a meta-analysis published in Urology.

31 Mar 2014

Actavis gets favorable ruling in patent suit against generic Lialda

Actavis plc today confirmed that the United States Court of Appeals for the Federal Circuit has reversed a lower court ruling that Actavis' generic version of Shire's Lialda (mesalamine extended-release tablets) infringes United States Patent No. 6,773,720 (the '720 Patent).

29 Mar 2014

Certain inherited DNA sequences may affect prognosis of bladder cancer patients

While patients diagnosed with bladder cancer usually face a favorable prognosis, many experience recurrence after treatment. Because frequent, painful screenings are needed to identify recurrences, the ablility to identify patients at high risk of recurrent cancer could help to improve quality of life for all bladder cancer patients.

29 Mar 2014

Scientists move a step closer to preserving fertility in young boys with cancer

Scientists have moved a step closer to being able to preserve fertility in young boys who undergo chemotherapy and radiation treatments for cancer. The new research, published in Fertility and Sterility, the journal of the American Society for Reproductive Medicine, addresses the safety of an option scientists are developing for boys who aren't sexually mature and cannot bank sperm.

28 Mar 2014

Patients with genetic variants are likely to experience bladder cancer recurrence

In the Western world, bladder cancer is the fourth most common cancer in men and the eighth most common in women, with many patients experiencing recurrence after treatment.

26 Mar 2014

Axonics Modulation Technologies completes $32.6 million Series A preferred stock financing

Axonics Modulation Technologies, Inc., a developer of novel implantable neuromodulation technology, announced today that it has completed a $32.6 million Series A preferred stock financing.

25 Mar 2014

PatientPoint signs distribution agreement with HealthTronics IT Solutions for urology technology

PatientPoint announced today that they have entered into a distribution agreement with HealthTronics IT Solutions to deliver population health management solutions within urology to drive improved adherence and compliance.

25 Mar 2014

Women with BRCA1 mutations may have increased risk for rare types of aggressive uterine cancer

Women with BRCA1 mutations may have an increased risk for developing rare types of aggressive uterine cancer despite having their ovaries and fallopian tubes removed, suggest preliminary findings being presented at the Society of Gynecologic Oncology (SGO) Annual Meeting on Women's Cancer in Tampa, Fla., March 22-25.

25 Mar 2014

Prostate stiffness is a risk factor for voiding dysfunction

Prostate elasticity is an independent risk factor for urinary voiding symptoms, although not for lower urinary tract symptoms in general or storage symptoms, clinical research indicates.

24 Mar 2014

Taiho Pharmaceutical obtains approval in Japan for anticancer drug Lonsurf

Taiho Pharmaceutical Co., Ltd. (Tokyo, President: Masayuki Kobayashi) announced on March 24 that it has obtained approval in Japan from the Ministry of Health, Labour and Welfare to manufacture and market the oral combination anticancer drug "Lonsurf(R) combination tablet T15, T20" (nonproprietary names: trifluridine and tipiracil hydrochloride; development code: TAS-102), for the treatment of patients with unresectable advanced or recurrent colorectal cancer (only if refractory to standard therapies).

24 Mar 2014